Background: Multiple recurrences after complete resection and irradiation of supratentorial ependymoma are common and frequently result in patient death. However, the molecular basis for treatment resistance, the impact that radiation and other adjuvant therapies have in promoting recurrence, and the use of this information to rationally design effective approaches to treat recurrent ependymoma are unknown. Due to the rarity of these tumors and the even less likely banking of multiple recurrent samples from the same patient, we initiated a study to characterize the evolution of a single patient's ependymoma in response to therapy.
Background
Ependymomas are a heterogeneous group of primary central nervous system tumors with multiple histological, brain region, age and molecular features distinguishing between different prognostic groups [1] [2] [3] ]. Overall, 10 year survival for children and adults with ependymomas is approximately 80%, with specific subsets of patients exhibiting survival of less than 30% at 10 years. Based on standard histological features, ependymal neoplasms can be diagnosed as World Health Organization (WHO) grade I, II or III tumors. However, in contrast to other brain tumors, histological grading has proven to be a weak prognostic indicator of outcome for ependymomas treated with standard-of-care complete surgical resection, with or without post-operative radiation therapy as indicated by the WHO grade [4] . Thus, there has been an increasing emphasis on the identification of prognostic molecular features that might provide more precise stratification for the risk of recurrence. For instance, young males harboring posterior fossa ependymomas found to exhibit a hypermethylator phenotype demonstrate poor survival [5] . Because the clinically distinguishing features of ependymoma include relatively common occurrence of multiple and late relapses, it is clear that improving outcomes and decreasing recurrence events will require a more complete understanding of tumor evolution after treatment.
To date, there is a paucity of information regarding the genomic changes in ependymomas that recur serially through multiple treatment regimens. This fact is largely due to the rarity of the disease and failure to bank and analyze recurrent samples. In order to determine the temporal genomic changes that occurred in one patient's ependymoma disease as it recurred after several different therapeutic modalities, we characterized the genomic landscape of serial resections with high depth next generation whole genome and exome sequencing. These data provided an evaluation of putative driver mutations, mutational signatures resulting from therapy, mechanisms for therapy response and resistance, and shifts in the neoantigen profile from the initial disease presentation through four recurrences.
Methods
Case history. The initial diagnosis was made in a 16 year-old right-handed female who presented to the St Louis Children's Hospital Emergency Department with a three-day history of headache and vomiting. MRI scan revealed a 6 cm x 4 cm enhancing mass in the right frontotemporal region (Fig 1A initial diagnosis) .
The patient underwent a gross total resection via a right frontotemporal craniotomy. Pathological evaluation was significant for a hypercellular glial tumor with prominent pseudo-rosettes, increased mitoses, vascular proliferation and necrosis, and perinuclear dot-like expression of epithelial membrane antigen (EMA , Fig 1   B , C) along-with diffuse glial fibrillary acidic protein immunoreactivity. A diagnosis of anaplastic ependymoma (WHO grade III) was made. Evaluations for central nervous system (CNS) dissemination were negative. The patient received 59.4 Gy of fractionated photon irradiation to the tumor bed plus a 1 cm margin, which is standard for supratentorial ependymoma. Forty-four months after the initial diagnosis, the patient suffered a seizure and an MRI revealed a 13 x 15 x 16 mm nodular recurrence in the right frontal lobe along the posterior margin of the initial resection cavity (Fig 1A first recurrence) . MRI of spine and cerebrospinal fluid cytology were negative. The patient underwent complete resection of the recurrent tumor, which exhibited similar histology to the initial tumor. The resection cavity and margin were reirradiated with an additional 59.4 Gy of fractionated photon irradiation and the patient received 10 months of standard dose temozolomide treatment.
A surveillance scan 17 months after the second resection demonstrated a 1 cm enhancing nodule in the temporal surface of the right sylvian fissure near the resection cavity, consistent with recurrence (Fig 1A   second recurrence) . Following a third complete resection, histopathology was again consistent with anaplastic ependymoma and analysis for dissemination was negative. The patient was enrolled on CERN-0801 at Children's Memorial Hospital in Chicago and received combined Avastin and Lapatinib. Lapatinib was discontinued four months later due to toxicity and Avastin was continued for an additional eight months for a total of one year of treatment every two weeks. Six months later, an MRI revealed a new right perisylvian lesion and right thalamic enhancing nodule (Fig 1A third recurrence) . Complete resection of the peri-sylvian lesion was performed and pathology again indicated anaplastic ependymoma (Fig 1D) with no evidence of dissemination. Avastin was restarted and continued for 20 months until new evidence from serial MRI indicated progression in a peri-sylvian lesion that had remained following the most recent surgery (Fig   1A fourth recurrence) . This lesion also was completely resected and diagnosed as anaplastic ependymoma. DNA sequencing. DNA was isolated from fresh frozen sections of each tumor resection using the Qiagen Dual Prep, and evaluated for quality and concentration using established methods. DNA was isolated from PBMC after Ficoll-based isolation to provide a normal comparator, and evaluated for quality and concentration. Using 500 ng input for all five tumors and the blood normal DNA, we generated two indexed whole genome sequencing libraries by standard methods (Kapa Biosystems) for each sample. One library per sample was processed through exome hybrid capture using the IDT EzExome reagent (Integrated DNA Technologies, Coralville IA), quantitated and amplified post-capture using the manufacturer's protocol.
Each of the corresponding WGS libraries was amplified by PCR, quantitated and diluted as appropriate for Illumina sequencing. The final libraries for each sample (WGS + exome) were pooled to produce combined tumor and normal WGS and exome sequencing data in a specific proportion, yielding ~10-fold WGS and ~1000-fold exome coverage (S1 Table) . The resulting library pools were loaded onto the HiSeqX platform and sequenced using 150 bp paired end reads.
Somatic variant analysis
After index-based binning of the reads into WGS-and exome-derived tumor and normal data, sequence data were aligned to reference sequence build GRCh37-lite-build37 using BWA mem[ref] version 0.7.10 (params: -t 8::), then merged and deduplicated using picard version 1.113, (https://broadinstitute.github.io/picard/). Somatic variants were called from the combined data using our Genome Modeling System (GMS) [6] as follows:
SNVs were detected using the union of four callers: 1) samtools [7] For protein-coding mutation counts described in the results below, a variant was considered to be present in a sample if it appeared with at least 3 variant supporting-reads and a VAF of > 2.5%. As some sites had low or variable coverage, a variant was only considered to be completely cleared if it did not appear in any subsequent samples.
Copy number aberrations were detected using bam-window (window-size 10000) and copy-cat version 1.6.11 (params: --per-read-length -per-library) (https://github.com/chrisamiller/copyCat). Uneven sequence coverage of the normal sample required us to run copyCat in tumor-only mode, followed by manual review to differentiate somatic from germline copy number events.
Putative structural variants were detected using the union of Breakdancer 1.4.5 [14] filtered by novo-realign and tigra-sv, and squaredancer 0.1 (https://github.com/genome/genome/blob/master/lib/perl/Genome/Model/Tools/Sv/SquareDancer.pl).
RNA sequencing. Total RNA was concurrently isolated from each fresh frozen tumor resection (Qiagen Dual Prep), and evaluated for quality and concentration using the Agilent Tapestation. RNAseq libraries were constructed using the TruSeq Stranded RNAseq library kit (Illumina, Inc., San Diego CA) according to the manufacturer's protocol, quantitated and diluted for sequencing. Using the HiSeq 2500, we produced sequencing data from each RNAseq library in a single flow cell lane by paired end 100 bp reads, yielding between 96 and 655 million reads per sample. The fourth recurrence sample was subjected to a capture step before sequencing, using the IDT EzExome reagent. This sample yielded 856 million reads, with a much higher coding-region percentage. (S1 Table) .
RNAseq analysis
The resulting read data were aligned to the human reference with Tophat v2.0.8 (denovo mode, params: -library-type fr-firststrand --bowtie-version=2.1.0). Expression levels were calculated with Cufflinks v2.1.1 (params: --max-bundle-length 10000000 --max-bundle-frags 10000000) [15] .
Gene Fusions
Gene fusions were detected from RNA and DNA using Integrate v0.2.0 [16] , with default parameters.
Data Deposition
All sequencing data are deposited in dbGAP study number [submission in progress]
Heterogeneity analysis.
Using the high depth of coverage from combining exome and WGS datasets for these tumors, we characterized the heterogeneity of each tumor specimen and compared it to the others in the series. Here, copy number-neutral variants and their attendant VAFs were clustered in five dimensions using the sciClone algorithm v1.1 [17] (parameters: minimumDepth=300, maximumClusters=15), followed by phylogeny reconstruction with clonEvol (https://github.com/hdng/clonevol).
Neoantigen predictions. Somatic mutations and RNAseq data from tumors were input into our pVAC-Seq pipeline [18] . WGS data from the normal blood was used to identify the patient's HLA haplotypes for class I, using HLAminer [19] . MHC class I binding predictions were generated through pVAC-Seq using NetMHC v3.4, as well as 5 other algorithms from the Immune Epitope Database and Analysis resource (IEDB, iedb.org): netMHC, netmhccons, netmhcpan, pickpocket, smm, and smmpmbec. Predictions were retained if the median score had an ic50 < 500 and better binding of the mutant peptide than the wild type (fold-change > 1). Results were then filtered to require expression of the mutant allele (FPKM > 1 and at least one variant-supporting read in the RNA). These combined data sets were used to identify neoantigenic peptide sequences in all five tumor samples, as illustrated in Fig 3c. Pathology methods. All the resection specimens (original and recurrences) were handled as regular surgical neuropathology cases. While hematoxylin and eosin stain and Ki-67 immunostain were performed on all the specimens, glial fibrillary acidic protein and epithelial membrane antigen were limited to the initial and 2014 resections.
Results

Mutational analysis of the matched normal sample
In order to determine whether the patient possessed a germline predisposition to cancer, we analyzed the sequence data obtained from her leukocyte-derived DNA (normal) and identified 176 protein-altering constitutional variants that were rare in the population and fell into highly-damaging classes of mutations (frameshifts, nonsense, nonstep, or splice-site) A full list of these is available at dbGAP accession xxxxxx) . Variants were recognized in several genes known to be important for immune function, including splice site SNPs in RAG1, HLA-DRB1, and HLA-DRB5, as well as a nonsense mutation in HLA-DRB5. Several cancer relevant genes were also observed: splice-site alterations in DDX3X [20] and MAD2L2 (alias: REV7) [24] , in-frame insertions in MNX1 [25] and ZFHX3, [26] . Some with direct glioma relevance were also observed: FOXD1 (in frame deletion) [27] [28] [29] , BCL2L2 (SNP) [30] , and RYK (frameshift insertion) [31] . The only predisposition-relevant gene was MNX1 (also known as HLXB9) which functions as an oncogene to promote pancreatic islet cell tumors in Multiple Endocrine Neoplasia Type 1 (MEN1) [32] .
Mutational landscape during disease progression
We identified 1,332 somatic mutations across the five resection specimens, 162 of which were in proteincoding regions, and 110 of which were non-silent (Fig 2, S2 Table) . The primary tumor sample contained only one overtly cancer-related gene mutation, an expressed frameshift insertion in MEN1 (K237fs) ( Table  1 ). We also observed several large copy number alterations (CNAs) in this sample, including deletions of 6p, 15q, 22, and the first 22Mb of chromosome 1, that were shared with the recurrent tumors. (S1 Figure, S3 Table) Chromosome 11 was heavily rearranged, with multiple distinct regions of amplification and deletion, one of which deleted the second copy of MEN1. Integrated analysis of the DNA and RNA only detected gene fusion events in the fourth recurrence, likely due to significantly higher depth and quality of the RNA sequencing data from that sample (S4 Table) . Many putative structural variants were detected in all samples (S5 Table) . All SNVs, indels and CNAs found in the initial resection were retained in the first recurrence, which was diagnosed after radiation therapy and a 44 month interval from the first surgery. An additional 12 new protein-coding somatic mutations were identified in the recurrent tumor, including a nonsense mutation in DEPDC5, an inhibitor of mTORC signaling. Missense mutations were observed in KREMEN2 (G165V), a gene that has been linked to melanoma, and in BANP (N223S), an epigenetic regulator. None are obviously expressed in this tumor, but the variants in both KREMEN2 and BANP are expressed in subsequent tumors with higher quality and higher-depth RNAseq, so it is likely that these variants are expressed below our level The second recurrent tumor emerged after additional radiation therapy and treatment with temozolomide. It was resected and the genomic analysis of this specimen indicated that essentially all previously observed mutations were retained, with the exception of 2 low-VAF protein-coding variants from the previous recurrence, including loss of the DEPDC5 nonsense mutation. An additional 66 protein-coding SNVs and indels were acquired, including a 19-bp frame-shift deletion in GPR124 and low-VAF missense mutations in was also observed. In addition to the NF2 mutation, we identified two point mutations that potentially impact Hippo pathway signaling in LATS1 and MAP4K3 [33] [34] .
Clonal heterogeneity and tumor evolution
To characterize the changing clonal architecture of this tumor, the variant allele fractions of copy-number neutral SNVs were clustered in 5 dimensions using the sciClone algorithm (Fig 3A) . Eight clusters were detected, and the mutation spectrum for each was identified. The first recurrent tumor after radiation therapy was dominated by Cluster 2, which emerged from a population of cells undetectable in our analysis of the original biopsy data (with a sensitivity of about ~2% VAF). The mutation spectrum shows a notable decrease in C>T transitions in cluster 2, as compared to those in cluster 1 from the original tumor (Fig 3B) .
We attempted mutational signature analysis [35] , but there were too few mutations to obtain statistically meaningful results. In the second recurrence, following additional radiation and treatment with temozolomide, we identified the emergence of two new subclonal populations (clusters 3 and 4) that were likewise undetectable in the prior two samples. Cluster 4, and all subsequently appearing clusters, each have a significantly higher proportion of A>G transitions than the founding clone, a pattern consistent with temozolomide-induced mutagenesis (all p < 0.03, S6 Table) [36] . In the third recurrence, following Avastin treatment, both clusters 3 and 4 were undetectable, but clusters 5 and 6 emerged. Although Cluster 6 was cleared in the final resection sample we studied, Cluster 5 persisted and two rare subclonal populations expanded into clusters 7 and 8, which make up a substantial portion of the final tumor. Some mutations in these two clusters were just above the level of detection in Sample 4.
In addition to identifying mutations correlated with specific subclonal expansions, we also examined the expression of O6-methylguanine DNA methyltransferase (MGMT), which is known to drive brain tumor recurrence through increased expression in post-temozolomide lesions [37, 38] . In this case, MGMT RNA expression levels were not clearly correlated with the emergence of post-temozolomide recurrences, suggesting that they relied upon alternative mechanisms of resistance (S2 Figure) Evolving landscape of targets for immunotherapy
In order to understand how the immunogenicity of this tumor evolved over the course of treatment, we applied the pVACSeq neoantigen prediction pipeline [18] to the protein-altering mutations that we observed in each tumor studied. The patient's HLA haplotypes were inferred to be A*24:02, A*26:01, B*40:02, B*38:01, C*12:03, and C*03:05. We identified only 14 expressed mutations that produce "high-quality" predicted MHC Class I neoantigens ( Fig 2C) , which we define as having median binding affinity (ic50) of less than 500nM, and with a higher binding affinity to the mutant than the wildtype peptide (S7 Table) . As overall mutation burden is highly correlated with neoantigen load, this is perhaps unsurprising. Only 3 neoantigens were present in the founding clone, while 11 of the 14 were specific to a subclonal population and therefore not present in all cells of the tumor.
Discussion
These data reveal new insights into molecular features of ependymoma and the effects of therapy on tumor evolution. Most notable is our identification of MEN1 mutation as a putative driver mutation, of potential mechanisms that contributed to tumor evolution, and of an observed GPR124 mutation that may serve as a prognostic indicator of response to Avastin.
MEN1 mutation and copy number loss
MEN1 mutations occur infrequently in ependymoma, both in the context of familial MEN1 syndrome and sporadically [39] [40][41] [42] . Whereas the genetics of supratentorial and infratentorial ependymoma, as well as the genetics of low grade (WHO grades I and II) and high grade (WHO grade III) ependymoma are most often reported to be distinct, MEN1 mutations occur, albeit rarely, in ependymomas of any grade and location. As is the case with the pathognomonic neoplasms of MEN1 syndrome, there is biallelic disruption of MEN1 in ependymomas. Two prior reports of recurrent ependymomas suggested that MEN1 mutation was associated with recurrence and progression from grade II to III [43] [41] . Ours is the first report to define the clonal architecture of primary and recurrent ependymoma and to identify MEN1 mutation as a feature of the founding clone.
It is important to consider the potential interaction between the altered MEN1 protein and germline altered cancer relevant proteins in the genesis of the initial tumor clone. In this regard, MNX1 expression is known to be regulated by Menin, the protein product of MEN1 . Though it has been reported that loss of Menin function increases MNX1 expression [32] ], and MNX1 has also been shown to function as an oncogene in driving pancreatic islet cell tumorigenesis [44] [45] [46] , we did not observe substantial expression of MNX1 in any of our tumors.
MEN1 dependent mechanisms in tumor evolution
Biochemical and genetic studies of Menin, the protein product of MEN1, have revealed complex and cell type specific functions that include roles in epigenetics, transcriptional regulation and regulation of intracellular signaling [47] . Of particular relevance to known ependymoma mechanisms are Menin's roles in DNA methylation and intracellular signaling pathways known to be involved in glioma biology, described below.
In both human MEN1 syndrome-associated tumors and mouse models of MEN1, loss of menin function results in increased DNA methyltransferase 1 (DNMT1) activity and global increases in CpG island methylation [48] . This CpG Island Methylator Phenotype (CIMP) is a known characteristic feature of colon cancer and a subset of high-grade gliomas, as well as a subset of ependymoma [49] [5] . Tumor suppressors known to be silenced by menin loss and to be relevant to glioma biology include CDKN1B, CDKN2A, APC and RASSF1A [50] [51] (PMID:16195383 ). The importance of altered epigenetic mechanisms to the biology of the ependymoma recurrences studied here is also suggested by the accumulation of mutations in additional epigenetic regulators through the course of its evolution (POU3F4, GON4L, HDAC3, SETD9, SUV39H1, BANP/SMAR1, FAM208A, PATZ1, KAT6B ).
Loss of menin function also is known to directly regulate multiple intracellular signaling pathways with established roles in gliomagenesis. Most relevant to glioma biology are the enhancing effects of menin loss on the activation of the RAS [52] , MAP kinase [53] , PI3 kinase [54] , Sonic Hedgehog [55] , Wnt [56] and TGF-b [57] signaling pathways. The importance of some of these mechanisms to the biology of this ependymoma is also suggested by the accumulation of mutations in additional regulators of their activation:
MAPK (SPRY3 [58] ), PI3K (DEPDC5 [58, 59] , WNT (KREMEN2 [60] [61], NET1 [62] , GPR124 [63] ).
In addition to the glioma-relevant pathways regulated by Menin, the Hippo pathway stands out as a compelling potential driver of the fourth recurrence, induced by new mutations in LATS1 (missense) and in NF2 (nonsense). NF2 loss-of-function mutations have been previously associated with spinal ependymomas [64] , and recent evidence suggests that YAP1, the nuclear target of Hippo signaling, mediates aberrant proliferation upon NF2 loss during tumorigenesis [65] . Furthermore, oncogenic YAP1 activation occurs as a consequence of a loss in NF2-dependent inactivation of LATS1, a key inhibitor of YAP1 [33, 65] . Decreased LATS1 activity has also been associated with glioma progression [33, 65, 66] .
GPR124 mutation as a potential prognostic indicator of Avastin Response
Additional striking features in the evolution of this ependymoma include the persistence of the founding clone and the unique response of the subclone arising in Recurrence 4 to Avastin and Lapatinib. This is the only substantial subclone to be completely eradicated by any element of treatment, suggesting an important relationship between this therapy and a target in this clone. Among the compelling target mediators of response or biomarkers of response is the mutation in GPR124. This orphan member of the adhesion G protein coupled receptor family is required specifically for the development of the brain vasculature [67] [68] [69] in a VEGF-dependent manner, and GPR124 may be a biomarker of Avastin response [70] .
GPR124 activates canonical Wnt signaling which, as described above, is normally directly inhibited by MEN1 and KREMEN2. The genes for both of these proteins were mutated in this tumor, suggesting a model for avastin response that might involve enhanced activation of a VEGF-Wnt axis. Additional study of samples before and after Avastin treatment is important to explore this possibility further.
Changes to the neoantigen landscape during progression
Overall, the number of expressed MHC Class I neoantigens that we predicted was low, as expected in a tumor with only 110 protein-altering mutations. The presence of a relatively high burden in the founding clone suggests that mechanisms of immune evasion were already present when the initial tumor presented, and may explain why there was no relationship between neoantigen load and subclonal response in subsequent tumors. This is supported by the observation that expression markers of T-cell activation were low in all five tumors.
Future Directions
These results suggest that radiation and chemotherapy contributed to the increasing complexity of this tumor by both adding to the mutational burden and expanding the subclonal architecture. Determining whether this natural history is generally true in ependymoma progression, and what impact therapy-induced tumor evolution has on outcome, is an important area of investigation with the potential to alter how we treat patients with completely resected supratentorial ependymoma. In the largest published study of ependymoma outcome involving 282 patients, gross total resection (GTR) was the only prognostic factor associated with increased survival [71] . In this analysis, GTR and post-surgical radiation therapy were associated with a shorter progression-free survival than GTR alone.
These clinical observations together with the sequencing-based characterizations presented here suggest that under some circumstances, adjuvant therapy may not be providing a benefit, and indeed may hasten recurrence by promoting molecular diversification of the tumor. We propose that this phenomenon be studied prospectively by sequencing completely resected supratentorial ependymomas and subsequent relapses to determine (a) the circumstances under which radiation therapy eradicates the founding clone and results in cure and (b) the circumstances under which tumors are resistant and instead exhibit an increase in their genomic complexity. Ultimately, it may be prudent to initially observe those patients with complete resections without additional therapy or to treat those patients whose tumors are likely to evolve in response to radiation therapy with targeted agents only as dictated by genomic analysis.
Finally, it will be important to investigate further the utility of genomic characterization to inform therapeutic options in this disease type. Although not all of the variants we identified were "druggable" in the classical sense, a subset were found to comprise predicted high affinity neoantigen targets that, ultimately, formed the basis of a polyvalent personalized vaccine, administered after recurrence 4. Although the efficacy of these treatments awaits large scale studies that are ongoing, our case highlights the potential to consider the pursuit of a personalized vaccine in extremely challenging settings of multiple recurrent disease such as the one herein, where few to no other options exist.
